It Takes a Team: Treating Adverse Events
A multidisciplinary care team is needed when treating patients who are given a combination of chemotherapy and immunotherapy.
When treating patients with chemotherapy plus an immunotherapy agent, a multidisciplinary team should be on call to manage adverse events (AEs), explained Matthew A. Gubens, MD, MS, associate professor of thoracic medical oncology at the UCSF Helen Diller Family Comprehensive Cancer Center.
The combination is usually well-tolerated, with typical chemotherapy AEs occurring, such as nausea and vomiting. When it comes to immunotherapy, the same AEs that would be expected if the drug was given as a single agent could be expected, Gubens said.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
Increasing Awareness of Audiovestibular Adverse Events From Immune Checkpoint Inhibitors
July 16th 2024Oncology nurses play a critical role in identifying and managing rare audiovestibular complications associated with immune checkpoint inhibitors to prevent permanent hearing loss and improve patients' quality of life.
